What question did this study set out to answer?

This pilot trial aims to compare the effectiveness of apixaban versus aspirin for thromboprophylaxis in JAK2-positive myeloproliferative neoplasms.

May 9, 2026HaematologicaOpen Access

Breaking barriers in rare disease research: a pilot trial of thromboprophylaxis with apixaban versus aspirin in JAK2-Positive myeloproliferative neoplasms

View Full Paper

Ask AI

Bookmark

Authors

Pilot trial evaluates thromboprophylaxis in JAK2-positive myeloproliferative neoplasms, suggesting new treatment pathways.

This pilot trial aims to compare the effectiveness of apixaban versus aspirin for thromboprophylaxis in JAK2-positive myeloproliferative neoplasms.
Pilot trial design
Participants with JAK2-positive myeloproliferative neoplasms
Comparison between apixaban and aspirin interventions
Detailed numerical results are not provided due to the lack of abstract information.

Kimpton et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark